December 07, 2015

GSK Selects Accenture’s Life Sciences Cloud for R&D to Simplify and Speed its Drug Development Process

NEW YORK; Dec. 7, 2015 – Accenture (NYSE: ACN) has announced GSK will use the Accenture Life Sciences Cloud for R&D platform to help simplify and speed up its drug development process. The platform brings together multiple internal and external data sources into a single analytics platform, creating actionable insights to accelerate drug development and improve patient outcomes.

GSK has also joined the Accenture Life Sciences Cloud Coalition, which already includes three prominent pharmaceutical companies: Eisai, Merck and Pfizer. The intention of the coalition is to drive innovation and digitally enable the R&D function through the Accenture Life Sciences Cloud for R&D platform.

“We believe GSK’s industry insights will help further shape the future of our industry,” said Kevin Julian, managing director in Accenture Accelerated R&D Services, Life Sciences. “The Accenture Life Sciences Cloud for R&D and Life Sciences Cloud Coalition are exciting initiatives that are bringing together like-minded leaders to collaborate for a stronger industry by creating significant R&D efficiencies in non-competitive areas.”

About Accenture
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions – underpinned by the world’s largest delivery network – Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With more than 358,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Its home page is

# # #


Cam Granstra
+ 1 312 693 5992

Stefanie Schumann
+ 1 312 693 1332